vs
Paycom（PAYC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Paycom的1.4倍（$772.1M vs $544.3M），Paycom净利率更高（20.9% vs 12.7%，领先8.2%），Paycom同比增速更快（10.2% vs 5.9%），Revvity自由现金流更多（$161.8M vs $122.6M），过去两年Revvity的营收复合增速更高（9.0% vs 4.3%）
Paycom Software Inc.（简称Paycom）是1998年成立的线上薪资与人力资源软件服务商，总部位于美国俄克拉荷马城，在全美多地设有办事处，是全球最早推出全线上薪资管理服务的供应商之一，2025年营收达20.52亿美元，较2024年的18.83亿美元稳步增长。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PAYC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$544.3M
营收增速更快
PAYC
高出4.4%
5.9%
净利率更高
PAYC
高出8.2%
12.7%
自由现金流更多
RVTY
多$39.2M
$122.6M
两年增速更快
RVTY
近两年复合增速
4.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $544.3M | $772.1M |
| 净利润 | $113.8M | $98.4M |
| 毛利率 | 83.9% | — |
| 营业利润率 | 28.9% | 14.5% |
| 净利率 | 20.9% | 12.7% |
| 营收同比 | 10.2% | 5.9% |
| 净利润同比 | 0.2% | 3.9% |
| 每股收益（稀释后） | $2.06 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAYCRVTY
| Q4 25 | $544.3M | $772.1M | ||
| Q3 25 | $493.3M | $698.9M | ||
| Q2 25 | $483.6M | $720.3M | ||
| Q1 25 | $530.5M | $664.8M | ||
| Q4 24 | $493.9M | $729.4M | ||
| Q3 24 | $451.9M | $684.0M | ||
| Q2 24 | $437.5M | $691.7M | ||
| Q1 24 | $499.9M | $649.9M |
净利润PAYCRVTY
| Q4 25 | $113.8M | $98.4M | ||
| Q3 25 | $110.7M | $46.7M | ||
| Q2 25 | $89.5M | $53.9M | ||
| Q1 25 | $139.4M | $42.2M | ||
| Q4 24 | $113.6M | $94.6M | ||
| Q3 24 | $73.3M | $94.4M | ||
| Q2 24 | $68.0M | $55.4M | ||
| Q1 24 | $247.2M | $26.0M |
毛利率PAYCRVTY
| Q4 25 | 83.9% | — | ||
| Q3 25 | 82.7% | 53.6% | ||
| Q2 25 | 81.9% | 54.5% | ||
| Q1 25 | 84.1% | 56.5% | ||
| Q4 24 | 83.1% | — | ||
| Q3 24 | 80.5% | 56.3% | ||
| Q2 24 | 80.8% | 55.7% | ||
| Q1 24 | 84.3% | 54.6% |
营业利润率PAYCRVTY
| Q4 25 | 28.9% | 14.5% | ||
| Q3 25 | 22.8% | 11.7% | ||
| Q2 25 | 23.2% | 12.6% | ||
| Q1 25 | 34.9% | 10.9% | ||
| Q4 24 | 30.1% | 16.3% | ||
| Q3 24 | 23.2% | 14.3% | ||
| Q2 24 | 21.7% | 12.4% | ||
| Q1 24 | 57.2% | 6.8% |
净利率PAYCRVTY
| Q4 25 | 20.9% | 12.7% | ||
| Q3 25 | 22.4% | 6.7% | ||
| Q2 25 | 18.5% | 7.5% | ||
| Q1 25 | 26.3% | 6.4% | ||
| Q4 24 | 23.0% | 13.0% | ||
| Q3 24 | 16.2% | 13.8% | ||
| Q2 24 | 15.5% | 8.0% | ||
| Q1 24 | 49.4% | 4.0% |
每股收益（稀释后）PAYCRVTY
| Q4 25 | $2.06 | $0.86 | ||
| Q3 25 | $1.96 | $0.40 | ||
| Q2 25 | $1.58 | $0.46 | ||
| Q1 25 | $2.48 | $0.35 | ||
| Q4 24 | $2.04 | $0.77 | ||
| Q3 24 | $1.31 | $0.77 | ||
| Q2 24 | $1.20 | $0.45 | ||
| Q1 24 | $4.37 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $370.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7B | $7.3B |
| 总资产 | $7.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PAYCRVTY
| Q4 25 | $370.0M | $919.9M | ||
| Q3 25 | $375.0M | $931.4M | ||
| Q2 25 | $532.2M | $991.8M | ||
| Q1 25 | $520.8M | $1.1B | ||
| Q4 24 | $402.0M | $1.2B | ||
| Q3 24 | $325.8M | $1.2B | ||
| Q2 24 | $346.5M | $2.0B | ||
| Q1 24 | $371.3M | $1.7B |
股东权益PAYCRVTY
| Q4 25 | $1.7B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.8B | $7.6B | ||
| Q1 25 | $1.7B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.5B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.4B | $7.8B |
总资产PAYCRVTY
| Q4 25 | $7.6B | $12.2B | ||
| Q3 25 | $4.2B | $12.1B | ||
| Q2 25 | $4.0B | $12.4B | ||
| Q1 25 | $4.6B | $12.4B | ||
| Q4 24 | $5.9B | $12.4B | ||
| Q3 24 | $3.5B | $12.8B | ||
| Q2 24 | $4.3B | $13.4B | ||
| Q1 24 | $4.7B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $196.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $122.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 22.5% | 21.0% |
| 资本支出强度资本支出/营收 | 13.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.72× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $408.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PAYCRVTY
| Q4 25 | $196.1M | $182.0M | ||
| Q3 25 | $177.8M | $138.5M | ||
| Q2 25 | $122.5M | $134.3M | ||
| Q1 25 | $182.5M | $128.2M | ||
| Q4 24 | $160.4M | $174.2M | ||
| Q3 24 | $92.8M | $147.9M | ||
| Q2 24 | $132.1M | $158.6M | ||
| Q1 24 | $148.6M | $147.6M |
自由现金流PAYCRVTY
| Q4 25 | $122.6M | $161.8M | ||
| Q3 25 | $79.8M | $120.0M | ||
| Q2 25 | $60.8M | $115.5M | ||
| Q1 25 | $144.8M | $112.2M | ||
| Q4 24 | $109.0M | $149.8M | ||
| Q3 24 | $44.6M | $125.6M | ||
| Q2 24 | $86.5M | $136.6M | ||
| Q1 24 | $100.9M | $129.7M |
自由现金流率PAYCRVTY
| Q4 25 | 22.5% | 21.0% | ||
| Q3 25 | 16.2% | 17.2% | ||
| Q2 25 | 12.6% | 16.0% | ||
| Q1 25 | 27.3% | 16.9% | ||
| Q4 24 | 22.1% | 20.5% | ||
| Q3 24 | 9.9% | 18.4% | ||
| Q2 24 | 19.8% | 19.7% | ||
| Q1 24 | 20.2% | 20.0% |
资本支出强度PAYCRVTY
| Q4 25 | 13.5% | 2.6% | ||
| Q3 25 | 19.9% | 2.6% | ||
| Q2 25 | 12.8% | 2.6% | ||
| Q1 25 | 7.1% | 2.4% | ||
| Q4 24 | 10.4% | 3.4% | ||
| Q3 24 | 10.7% | 3.3% | ||
| Q2 24 | 10.4% | 3.2% | ||
| Q1 24 | 9.5% | 2.7% |
现金转化率PAYCRVTY
| Q4 25 | 1.72× | 1.85× | ||
| Q3 25 | 1.61× | 2.97× | ||
| Q2 25 | 1.37× | 2.49× | ||
| Q1 25 | 1.31× | 3.03× | ||
| Q4 24 | 1.41× | 1.84× | ||
| Q3 24 | 1.27× | 1.57× | ||
| Q2 24 | 1.94× | 2.87× | ||
| Q1 24 | 0.60× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAYC
| Recurring | $510.3M | 94% |
| Interest On Funds Held For Clients | $27.2M | 5% |
| Implementation And Other | $6.8M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
